{"transactions":[{"id":683585,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance Stock Units","published_at":"2026-08-18T20:05:10.000Z","date":"2026-08-15","kind":"grant","planned":false,"acquired":true,"shares":60492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents performance-based restricted stock units (\"PSUs\") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each PSU represents a conditional right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":137651,"derivative":{"underlying":"Common Stock","underlying_shares":60492},"source":{"system":"sec-edgar","filing":"0001711462-26-000014","document":"form4-08182026_040804.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000014/form4-08182026_040804.xml","form_type":"4"}},{"id":693090,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance Stock Units","published_at":"2026-08-07T21:13:24.000Z","date":"2026-03-12","kind":"grant","planned":false,"acquired":true,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents performance-based restricted stock units (\"PSUs\") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 12, 2026."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each PSU represents a conditional right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs vest and settle over two years; 50% vests on March 12, 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs vest and settle over two years; 50% vests on March 12, 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":16667,"derivative":{"underlying":"Common Stock","underlying_shares":16667},"source":{"system":"sec-edgar","filing":"0001711462-26-000012","document":"form4-08072026_090818.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000012/form4-08072026_090818.xml","form_type":"4"}},{"id":695754,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance Stock Units","published_at":"2026-08-05T22:25:48.000Z","date":"2026-08-02","kind":"grant","planned":false,"acquired":true,"shares":60492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents performance-based restricted stock units (\"PSUs\") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 2, 2026."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each PSU represents a conditional right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs vest and settle over two years; 50% vests on August 2, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs vest and settle over two years; 50% vests on August 2, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":77159,"derivative":{"underlying":"Common Stock","underlying_shares":60492},"source":{"system":"sec-edgar","filing":"0001711462-26-000011","document":"form4-08052026_100845.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000011/form4-08052026_100845.xml","form_type":"4"}},{"id":779247,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-05-14T20:05:07.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":72300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 25% of the total shares on May 12, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"In addition to the options to purchase a total of 72,300 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 507,310 shares of common stock, which options vest according to their terms."}],"balance_after":72300,"derivative":{"exercise_price":17.81,"expiration_date":"2036-05-11","underlying":"Common Stock","underlying_shares":72300},"source":{"system":"sec-edgar","filing":"0001711462-26-000010","document":"form4-05142026_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000010/form4-05142026_040501.xml","form_type":"4"}},{"id":779246,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-05-14T20:05:07.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":26700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":26700,"derivative":{"underlying":"Common Stock","underlying_shares":26700},"source":{"system":"sec-edgar","filing":"0001711462-26-000010","document":"form4-05142026_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000010/form4-05142026_040501.xml","form_type":"4"}},{"id":802880,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:24.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":21400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F8","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":21400,"derivative":{"underlying":"Common Stock","underlying_shares":21400},"source":{"system":"sec-edgar","filing":"0001711462-26-000009","document":"form4-04222026_040419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000009/form4-04222026_040419.xml","form_type":"4"}},{"id":802879,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:24.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":25575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F8","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25575,"derivative":{"underlying":"Common Stock","underlying_shares":25575},"source":{"system":"sec-edgar","filing":"0001711462-26-000009","document":"form4-04222026_040419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000009/form4-04222026_040419.xml","form_type":"4"}},{"id":802878,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:24.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":21110,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F8","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":21110,"derivative":{"underlying":"Common Stock","underlying_shares":21110},"source":{"system":"sec-edgar","filing":"0001711462-26-000009","document":"form4-04222026_040419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000009/form4-04222026_040419.xml","form_type":"4"}},{"id":802877,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-04-22T20:05:24.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":6145,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F8","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding RSU with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSU s with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6145,"derivative":{"underlying":"Common Stock","underlying_shares":6145},"source":{"system":"sec-edgar","filing":"0001711462-26-000009","document":"form4-04222026_040419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000009/form4-04222026_040419.xml","form_type":"4"}},{"id":802876,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:24.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":29000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":29000,"derivative":{"exercise_price":11.75,"expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":29000},"source":{"system":"sec-edgar","filing":"0001711462-26-000009","document":"form4-04222026_040419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000009/form4-04222026_040419.xml","form_type":"4"}},{"id":802875,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:24.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":97200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":97200,"derivative":{"exercise_price":3.97,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":97200},"source":{"system":"sec-edgar","filing":"0001711462-26-000009","document":"form4-04222026_040419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000009/form4-04222026_040419.xml","form_type":"4"}},{"id":802874,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:24.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":115540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":115540,"derivative":{"exercise_price":5.67,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":115540},"source":{"system":"sec-edgar","filing":"0001711462-26-000009","document":"form4-04222026_040419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000009/form4-04222026_040419.xml","form_type":"4"}},{"id":802873,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:24.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":67070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":67070,"derivative":{"exercise_price":6.22,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":67070},"source":{"system":"sec-edgar","filing":"0001711462-26-000009","document":"form4-04222026_040419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000009/form4-04222026_040419.xml","form_type":"4"}},{"id":802872,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:24.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":70000,"derivative":{"exercise_price":8.14,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001711462-26-000009","document":"form4-04222026_040419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000009/form4-04222026_040419.xml","form_type":"4"}},{"id":802871,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:24.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":45000,"derivative":{"exercise_price":7.95,"expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001711462-26-000009","document":"form4-04222026_040419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000009/form4-04222026_040419.xml","form_type":"4"}},{"id":802870,"issuer":{"id":4696,"kind":"organization","name":"First Tracks Biotherapeutics, Inc.","symbol":"TRAX"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-22T20:05:24.000Z","date":"2026-04-20","kind":"grant","planned":false,"acquired":true,"shares":83500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the \"Separation Agreement\"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exercisable."}],"balance_after":83500,"derivative":{"exercise_price":4.95,"expiration_date":"2030-07-29","underlying":"Common Stock","underlying_shares":83500},"source":{"system":"sec-edgar","filing":"0001711462-26-000009","document":"form4-04222026_040419.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000009/form4-04222026_040419.xml","form_type":"4"}},{"id":942150,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-10T00:16:03.000Z","date":"2026-01-07","kind":"exercise","planned":false,"acquired":false,"shares":8525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25575,"derivative":{"underlying":"Common Stock","underlying_shares":8525},"source":{"system":"sec-edgar","filing":"0001711462-26-000006","document":"form4-01102026_120159.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000006/form4-01102026_120159.xml","form_type":"4"}},{"id":942149,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-10T00:16:03.000Z","date":"2026-01-08","kind":"sale","planned":false,"acquired":false,"shares":3650,"price":44.71,"value":163191.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":42088,"source":{"system":"sec-edgar","filing":"0001711462-26-000006","document":"form4-01102026_120159.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000006/form4-01102026_120159.xml","form_type":"4"}},{"id":942148,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-10T00:16:03.000Z","date":"2026-01-07","kind":"exercise","planned":false,"acquired":true,"shares":8525,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":45738,"source":{"system":"sec-edgar","filing":"0001711462-26-000006","document":"form4-01102026_120159.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000006/form4-01102026_120159.xml","form_type":"4"}},{"id":943256,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-08T21:11:24.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":29000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":29000,"derivative":{"exercise_price":43.91,"expiration_date":"2036-01-05","underlying":"Common Stock","underlying_shares":29000},"source":{"system":"sec-edgar","filing":"0001711462-26-000004","document":"form4-01082026_090121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000004/form4-01082026_090121.xml","form_type":"4"}},{"id":943255,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-08T21:11:24.000Z","date":"2026-01-06","kind":"grant","planned":false,"acquired":true,"shares":21400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":21400,"derivative":{"underlying":"Common Stock","underlying_shares":21400},"source":{"system":"sec-edgar","filing":"0001711462-26-000004","document":"form4-01082026_090121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000004/form4-01082026_090121.xml","form_type":"4"}},{"id":943254,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-08T21:11:24.000Z","date":"2026-01-06","kind":"exercise","planned":false,"acquired":false,"shares":6145,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6145,"derivative":{"underlying":"Common Stock","underlying_shares":6145},"source":{"system":"sec-edgar","filing":"0001711462-26-000004","document":"form4-01082026_090121.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000004/form4-01082026_090121.xml","form_type":"4"}},{"id":943253,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-08T21:11:24.000Z","date":"2026-01-07","kind":"sale","planned":false,"acquired":false,"shares":2235,"price":45.11,"value":100820.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":37213,"source":{"system":"sec-edgar","filing":"0001711462-26-000004","document":"form4-01082026_090121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000004/form4-01082026_090121.xml","form_type":"4"}},{"id":943252,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-08T21:11:24.000Z","date":"2026-01-06","kind":"exercise","planned":false,"acquired":true,"shares":6145,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":39448,"source":{"system":"sec-edgar","filing":"0001711462-26-000004","document":"form4-01082026_090121.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000004/form4-01082026_090121.xml","form_type":"4"}},{"id":946835,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-07T02:04:49.000Z","date":"2026-01-03","kind":"exercise","planned":false,"acquired":false,"shares":10555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":21110,"derivative":{"underlying":"Common Stock","underlying_shares":10555},"source":{"system":"sec-edgar","filing":"0001711462-26-000002","document":"form4-01072026_020144.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000002/form4-01072026_020144.xml","form_type":"4"}},{"id":946834,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-07T02:04:49.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":4219,"price":43.26,"value":182513.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":33303,"source":{"system":"sec-edgar","filing":"0001711462-26-000002","document":"form4-01072026_020144.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000002/form4-01072026_020144.xml","form_type":"4"}},{"id":946833,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-07T02:04:49.000Z","date":"2026-01-03","kind":"exercise","planned":false,"acquired":true,"shares":10555,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":37522,"source":{"system":"sec-edgar","filing":"0001711462-26-000002","document":"form4-01072026_020144.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146226000002/form4-01072026_020144.xml","form_type":"4"}},{"id":959670,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-23T21:28:44.000Z","date":"2025-12-22","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"In addition to the remaining options to purchase 83,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 394,810 shares of common stock, which options vest according to their terms."}],"balance_after":83500,"derivative":{"exercise_price":18.5,"expiration_date":"2030-07-29","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001711462-25-000003","document":"form4-12232025_091241.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146225000003/form4-12232025_091241.xml","form_type":"4"}},{"id":959669,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-23T21:28:44.000Z","date":"2025-12-22","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":50,"value":75000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2025."}],"balance_after":26967,"source":{"system":"sec-edgar","filing":"0001711462-25-000003","document":"form4-12232025_091241.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146225000003/form4-12232025_091241.xml","form_type":"4"}},{"id":959668,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-23T21:28:44.000Z","date":"2025-12-22","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":18.5,"value":27750.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes the acquisition of 1,324 shares acquired under the Company's ESPP."}],"balance_after":28467,"source":{"system":"sec-edgar","filing":"0001711462-25-000003","document":"form4-12232025_091241.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000171146225000003/form4-12232025_091241.xml","form_type":"4"}},{"id":1308117,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T22:33:21.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":97200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":97200,"derivative":{"exercise_price":14.83,"expiration_date":"2035-01-06","underlying":"Common Stock","underlying_shares":97200},"source":{"system":"sec-edgar","filing":"0001415889-25-001046","document":"form4-01072025_100117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588925001046/form4-01072025_100117.xml","form_type":"4"}},{"id":1308116,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-01-07T22:33:21.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":34100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":34100,"derivative":{"underlying":"Common Stock","underlying_shares":34100},"source":{"system":"sec-edgar","filing":"0001415889-25-001046","document":"form4-01072025_100117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588925001046/form4-01072025_100117.xml","form_type":"4"}},{"id":1308115,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-01-07T22:33:21.000Z","date":"2025-01-06","kind":"exercise","planned":false,"acquired":false,"shares":6145,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12290,"derivative":{"underlying":"Common Stock","underlying_shares":6145},"source":{"system":"sec-edgar","filing":"0001415889-25-001046","document":"form4-01072025_100117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588925001046/form4-01072025_100117.xml","form_type":"4"}},{"id":1308114,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-01-07T22:33:21.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":false,"shares":10555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":31665,"derivative":{"underlying":"Common Stock","underlying_shares":10555},"source":{"system":"sec-edgar","filing":"0001415889-25-001046","document":"form4-01072025_100117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588925001046/form4-01072025_100117.xml","form_type":"4"}},{"id":1308113,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-07T22:33:21.000Z","date":"2025-01-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":2261,"price":15.3,"value":34593.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation."},{"field":"shares","element":"transactionShares","label":"F4","text":"The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes."}],"balance_after":25643,"source":{"system":"sec-edgar","filing":"0001415889-25-001046","document":"form4-01072025_100117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588925001046/form4-01072025_100117.xml","form_type":"4"}},{"id":1308112,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-07T22:33:21.000Z","date":"2025-01-06","kind":"exercise","planned":false,"acquired":true,"shares":6145,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":27904,"source":{"system":"sec-edgar","filing":"0001415889-25-001046","document":"form4-01072025_100117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588925001046/form4-01072025_100117.xml","form_type":"4"}},{"id":1308111,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-07T22:33:21.000Z","date":"2025-01-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":4336,"price":14.6,"value":63305.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer to satisfy a portion of the tax withholding obligation in connection with the vesting of RSUs and do not represent discretionary transactions by the Reporting Person. Following the transactions reflecting in this Form 4, no additional transactions are expected to satisfy the Reporting Person's tax withholding obligation."},{"field":"shares","element":"transactionShares","label":"F4","text":"The Reporting Person did not sell or otherwise dispose of any of the shares with respect to the vesting of RSUs reported on this Form 4 for any reason other than to cover required taxes."}],"balance_after":21759,"source":{"system":"sec-edgar","filing":"0001415889-25-001046","document":"form4-01072025_100117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588925001046/form4-01072025_100117.xml","form_type":"4"}},{"id":1308110,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-07T22:33:21.000Z","date":"2025-01-03","kind":"exercise","planned":false,"acquired":true,"shares":10555,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the acquisition of 142 shares acquired under the Company's ESPP."}],"balance_after":26095,"source":{"system":"sec-edgar","filing":"0001415889-25-001046","document":"form4-01072025_100117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588925001046/form4-01072025_100117.xml","form_type":"4"}},{"id":1400164,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common","published_at":"2024-09-24T20:18:25.000Z","date":"2024-09-23","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"In addition to the remaining options to purchase 85,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 297,610 shares of common stock, which options vest according to their terms."}],"balance_after":85000,"derivative":{"exercise_price":18.5,"expiration_date":"2030-07-29","underlying":"Common","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001415889-24-023900","document":"form4-09242024_080920.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588924023900/form4-09242024_080920.xml","form_type":"4"}},{"id":1400163,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-09-24T20:18:25.000Z","date":"2024-09-23","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":38.67,"value":58005.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2024."}],"balance_after":15398,"source":{"system":"sec-edgar","filing":"0001415889-24-023900","document":"form4-09242024_080920.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588924023900/form4-09242024_080920.xml","form_type":"4"}},{"id":1400162,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-09-24T20:18:25.000Z","date":"2024-09-23","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":18.5,"value":27750.0,"ownership":{"direct":true},"balance_after":16898,"source":{"system":"sec-edgar","filing":"0001415889-24-023900","document":"form4-09242024_080920.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588924023900/form4-09242024_080920.xml","form_type":"4"}},{"id":1405126,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-09-17T22:42:11.000Z","date":"2024-09-14","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50% of the total restricted stock units vested on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"50% of the total restricted stock units vested on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001415889-24-023550","document":"form4-09172024_100907.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588924023550/form4-09172024_100907.xml","form_type":"4"}},{"id":1405125,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-09-17T22:42:11.000Z","date":"2024-09-16","kind":"sale","planned":true,"acquired":false,"shares":2220,"price":38.93,"value":86424.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":15398,"source":{"system":"sec-edgar","filing":"0001415889-24-023550","document":"form4-09172024_100907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588924023550/form4-09172024_100907.xml","form_type":"4"}},{"id":1405124,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-09-17T22:42:11.000Z","date":"2024-09-14","kind":"exercise","planned":true,"acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":17618,"source":{"system":"sec-edgar","filing":"0001415889-24-023550","document":"form4-09172024_100907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588924023550/form4-09172024_100907.xml","form_type":"4"}},{"id":1431394,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common","published_at":"2024-08-16T20:09:38.000Z","date":"2024-08-14","kind":"exercise","planned":true,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"In addition to the remaining options to purchase 86,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 297,610 shares of common stock, which options vest according to their terms."}],"balance_after":86500,"derivative":{"exercise_price":18.5,"expiration_date":"2030-07-29","underlying":"Common","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001415889-24-021452","document":"form4-08162024_080835.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588924021452/form4-08162024_080835.xml","form_type":"4"}},{"id":1431393,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-16T20:09:38.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":40,"value":80000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2023."}],"balance_after":11618,"source":{"system":"sec-edgar","filing":"0001415889-24-021452","document":"form4-08162024_080835.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588924021452/form4-08162024_080835.xml","form_type":"4"}},{"id":1431392,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-08-16T20:09:38.000Z","date":"2024-08-14","kind":"exercise","planned":true,"acquired":true,"shares":2000,"price":18.5,"value":37000.0,"ownership":{"direct":true},"balance_after":13618,"source":{"system":"sec-edgar","filing":"0001415889-24-021452","document":"form4-08162024_080835.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588924021452/form4-08162024_080835.xml","form_type":"4"}},{"id":1449375,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-24T20:15:15.000Z","date":"2024-07-22","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit (\"PSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on July 22, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of certain share price metrics (\"Performance Metrics\"). 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026.  An additional 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the 2-year anniversary of such achievement (but not later than July 1, 2028), subject to the Reporting Person' service to the Issue on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on July 22, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of certain share price metrics (\"Performance Metrics\"). 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the later of (i) the 1-year anniversary of the achievement of such applicable Performance Metrics and (ii) on July 1, 2026.  An additional 50% of the total number of shares subject to the PSU that achieves the applicable Performance Metrics shall vest on the 2-year anniversary of such achievement (but not later than July 1, 2028), subject to the Reporting Person' service to the Issue on each vesting date."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-24-020036","document":"form4-07242024_080712.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588924020036/form4-07242024_080712.xml","form_type":"4"}},{"id":1451215,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common","published_at":"2024-07-20T00:35:44.000Z","date":"2024-07-18","kind":"exercise","planned":true,"acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"In addition to the remaining options to purchase 88,500 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 297,610 shares of common stock, which options vest according to their terms."}],"balance_after":88500,"derivative":{"exercise_price":18.5,"expiration_date":"2030-07-30","underlying":"Common","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001415889-24-019829","document":"form4-07202024_120740.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588924019829/form4-07202024_120740.xml","form_type":"4"}},{"id":1451214,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-20T00:35:44.000Z","date":"2024-07-18","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":35,"value":52500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2023."}],"balance_after":11618,"source":{"system":"sec-edgar","filing":"0001415889-24-019829","document":"form4-07202024_120740.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588924019829/form4-07202024_120740.xml","form_type":"4"}},{"id":1451213,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-07-20T00:35:44.000Z","date":"2024-07-18","kind":"exercise","planned":true,"acquired":true,"shares":1500,"price":18.5,"value":27750.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects the acquisition of 1,500 shares acquired under the Company's ESPP."}],"balance_after":13118,"source":{"system":"sec-edgar","filing":"0001415889-24-019829","document":"form4-07202024_120740.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000141588924019829/form4-07202024_120740.xml","form_type":"4"}},{"id":1682757,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-01-10T00:08:05.000Z","date":"2024-01-06","kind":"exercise","planned":false,"acquired":false,"shares":6145,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":18435,"derivative":{"underlying":"Common Stock","underlying_shares":6145},"source":{"system":"sec-edgar","filing":"0001209191-24-001280","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919124001280/doc4.xml","form_type":"4"}},{"id":1682756,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-10T00:08:05.000Z","date":"2024-01-08","kind":"sale","planned":false,"acquired":false,"shares":2554,"price":21.81,"value":55702.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":10118,"source":{"system":"sec-edgar","filing":"0001209191-24-001280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919124001280/doc4.xml","form_type":"4"}},{"id":1682755,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-10T00:08:05.000Z","date":"2024-01-06","kind":"exercise","planned":false,"acquired":true,"shares":6145,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":12672,"source":{"system":"sec-edgar","filing":"0001209191-24-001280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919124001280/doc4.xml","form_type":"4"}},{"id":1685550,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-01-05T22:00:33.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":42220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":42220,"derivative":{"underlying":"Common Stock","underlying_shares":42220},"source":{"system":"sec-edgar","filing":"0001209191-24-001052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919124001052/doc4.xml","form_type":"4"}},{"id":1685549,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T22:00:33.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":115540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":115540,"derivative":{"exercise_price":21.19,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":115540},"source":{"system":"sec-edgar","filing":"0001209191-24-001052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919124001052/doc4.xml","form_type":"4"}},{"id":1778954,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2023-09-18T22:14:49.000Z","date":"2023-09-14","kind":"exercise","planned":false,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":6000,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-23-049810","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919123049810/doc4.xml","form_type":"4"}},{"id":1778953,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-09-18T22:14:49.000Z","date":"2023-09-14","kind":"sale","planned":false,"acquired":false,"shares":2105,"price":19.48,"value":41005.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":6527,"source":{"system":"sec-edgar","filing":"0001209191-23-049810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919123049810/doc4.xml","form_type":"4"}},{"id":1778952,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-09-18T22:14:49.000Z","date":"2023-09-14","kind":"exercise","planned":false,"acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the acquisition of 881 shares acquired under the Company's ESPP."}],"balance_after":8632,"source":{"system":"sec-edgar","filing":"0001209191-23-049810","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919123049810/doc4.xml","form_type":"4"}},{"id":2057530,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2023-01-11T00:07:40.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":24580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock award (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":24580,"derivative":{"underlying":"Common Stock","underlying_shares":24580},"source":{"system":"sec-edgar","filing":"0001209191-23-002880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919123002880/doc4.xml","form_type":"4"}},{"id":2057529,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-11T00:07:40.000Z","date":"2023-01-06","kind":"grant","acquired":true,"shares":67070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":67070,"derivative":{"exercise_price":23.23,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":67070},"source":{"system":"sec-edgar","filing":"0001209191-23-002880","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919123002880/doc4.xml","form_type":"4"}},{"id":2157402,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-09-16T21:08:20.000Z","date":"2022-09-14","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents a one-time retention grant of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the total RSUs vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"50% of the total RSUs vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"In addition to the remaining options to purchase 12,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 215,000 shares of common stock, which options vest according to their terms, and (ii) 1,751 shares of common stock held directly."}],"balance_after":12000,"derivative":{"underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-22-050354","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919122050354/doc4.xml","form_type":"4"}},{"id":2221172,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-06-27T23:03:20.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 10, 2021, the reporting person was granted a performance-based option to purchase 10,000 shares of the Issuer's common stock, subject to the achievement of certain corporate performance criteria and the reporting person's continued service to the Issuer upon achievement thereof.  The performance criteria were achieved on the date in Column 3, resulting in the vesting of the entire award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 205,000 shares of common stock, which options vest according to their terms, and (ii) 1,751 shares of common stock held directly."}],"balance_after":10000,"derivative":{"exercise_price":29.7,"exercise_date":"2022-06-23","expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-22-039531","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919122039531/doc4.xml","form_type":"4"}},{"id":2398147,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-14T21:55:25.000Z","date":"2022-02-10","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2023, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In addition to the remaining options to purchase 70,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 135,000 shares of common stock, which options vest according to their terms, and (ii) 964 shares of common stock held directly."}],"balance_after":70000,"derivative":{"exercise_price":30.44,"expiration_date":"2032-02-09","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-22-009364","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919122009364/doc4.xml","form_type":"4"}},{"id":2507515,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-11-17T22:22:50.000Z","date":"2021-11-15","kind":"grant","acquired":true,"shares":964,"price":22.03,"value":21236.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock acquired pursuant to the Issuer's Employee Stock Purchase Plan (\"ESPP\"), for the purchase period through November 15, 2021. In accordance with the ESPP, these shares were purchased at 85% of the lesser of the closing price of the Issuer's Common Stock on May 17, 2021 and November 15, 2021."}],"balance_after":964,"source":{"system":"sec-edgar","filing":"0001209191-21-065178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919121065178/doc4.xml","form_type":"4"}},{"id":2863500,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-13T02:42:44.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2022, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":45000,"derivative":{"exercise_price":29.7,"expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-21-010533","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919121010533/doc4.xml","form_type":"4"}},{"id":3072566,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-07-31T20:18:33.000Z","date":"2020-07-30","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":90000,"derivative":{"exercise_price":18.5,"expiration_date":"2030-07-30","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-20-044259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000120919120044259/doc4.xml","form_type":"4"}},{"id":3443677,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T20:40:10.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":22500,"derivative":{"exercise_price":0.71,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001562180-19-004217","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019004217/primarydocument.xml","form_type":"4"}},{"id":3443676,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T20:40:10.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":22500,"derivative":{"exercise_price":0.71,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001562180-19-004217","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019004217/primarydocument.xml","form_type":"4"}},{"id":3443675,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T20:40:10.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":14904,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."}],"balance_after":14904,"derivative":{"exercise_price":0.71,"exercise_date":"2019-01-01","expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":14904},"source":{"system":"sec-edgar","filing":"0001562180-19-004217","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019004217/primarydocument.xml","form_type":"4"}},{"id":3443674,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T20:40:10.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":48720,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":48720,"derivative":{"exercise_price":0.71,"expiration_date":"2028-06-01","underlying":"Common Stock","underlying_shares":48720},"source":{"system":"sec-edgar","filing":"0001562180-19-004217","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019004217/primarydocument.xml","form_type":"4"}},{"id":3443673,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T20:40:10.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":11926,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Twenty-Five percent (25%) of the share subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":11926,"derivative":{"exercise_price":0.71,"expiration_date":"2027-07-26","underlying":"Common Stock","underlying_shares":11926},"source":{"system":"sec-edgar","filing":"0001562180-19-004217","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019004217/primarydocument.xml","form_type":"4"}},{"id":3443672,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T20:40:10.000Z","date":"2019-08-06","kind":"disposition_to_issuer","acquired":false,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":2.32,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001562180-19-004217","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019004217/primarydocument.xml","form_type":"4"}},{"id":3443671,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T20:40:10.000Z","date":"2019-08-06","kind":"disposition_to_issuer","acquired":false,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":2.32,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001562180-19-004217","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019004217/primarydocument.xml","form_type":"4"}},{"id":3443670,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T20:40:10.000Z","date":"2019-08-06","kind":"disposition_to_issuer","acquired":false,"shares":14904,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."}],"balance_after":0,"derivative":{"exercise_price":2.32,"exercise_date":"2019-01-01","expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":14904},"source":{"system":"sec-edgar","filing":"0001562180-19-004217","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019004217/primarydocument.xml","form_type":"4"}},{"id":3443669,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T20:40:10.000Z","date":"2019-08-06","kind":"disposition_to_issuer","acquired":false,"shares":11926,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Twenty-Five percent (25%) of the share subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2027-07-26","underlying":"Common Stock","underlying_shares":11926},"source":{"system":"sec-edgar","filing":"0001562180-19-004217","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019004217/primarydocument.xml","form_type":"4"}},{"id":3443668,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-08-08T20:40:10.000Z","date":"2019-08-06","kind":"disposition_to_issuer","acquired":false,"shares":48720,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported herein reflect a one-time stock option repricing (the \"Option Repricing\") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934.  Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71.  There have been no other changes to the terms of the relevant options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":15.08,"expiration_date":"2028-06-01","underlying":"Common Stock","underlying_shares":48720},"source":{"system":"sec-edgar","filing":"0001562180-19-004217","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019004217/primarydocument.xml","form_type":"4"}},{"id":3443667,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-08-08T20:40:10.000Z","date":"2019-08-06","kind":"grant","acquired":true,"shares":55000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Award of restricted stock units (\"RSUs\") granted under the Issuer's 2017 Incentive Award Plan.  Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting.  The award vests as to fifty percent (50%) of the total number of RSUs on February 6, 2020, twenty-five percent (25%) of the total number of RSUs on August 6, 2020, and the remaining twenty-five percent (25%) of the total number of RSUs on February 6, 2021, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes a total of 5,949 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":196488,"source":{"system":"sec-edgar","filing":"0001562180-19-004217","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019004217/primarydocument.xml","form_type":"4"}},{"id":3468190,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-07-03T17:39:14.000Z","date":"2019-07-02","kind":"tax_withholding","acquired":false,"shares":4095,"price":0.76,"value":3112.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares otherwise issuable to the Reporting Person that were withheld to satisfy the Issuer's tax withholding obligation upon settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $0.72 to $0.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes a total of 5,949 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":141488,"source":{"system":"sec-edgar","filing":"0001562180-19-003850","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019003850/primarydocument.xml","form_type":"4"}},{"id":3709344,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-01-03T23:16:37.000Z","date":"2019-01-01","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":2.32,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001562180-19-000148","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019000148/primarydocument.xml","form_type":"4"}},{"id":3709343,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-01-03T23:16:37.000Z","date":"2019-01-01","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":22500,"derivative":{"exercise_price":2.32,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001562180-19-000148","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019000148/primarydocument.xml","form_type":"4"}},{"id":3709342,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2019-01-03T23:16:37.000Z","date":"2019-01-01","kind":"grant","acquired":true,"shares":14904,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14904,"derivative":{"exercise_price":2.32,"exercise_date":"2019-01-01","expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":14904},"source":{"system":"sec-edgar","filing":"0001562180-19-000148","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019000148/primarydocument.xml","form_type":"4"}},{"id":3709341,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-01-03T23:16:37.000Z","date":"2019-01-01","kind":"grant","acquired":true,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Award of restricted stock units (\"RSUs\") granted under the Issuer's 2017 Incentive Award Plan.  Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting.  The award vests as to twenty-five percent (25%) of the total number of RSUs on July 1, 2019, twenty-five percent (25%) of the total number of RSUs on January 1, 2020, and the remaining fifty percent (50%) of the total number of RSUs on the second anniversary, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes a total of 2,949 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":142583,"source":{"system":"sec-edgar","filing":"0001562180-19-000148","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218019000148/primarydocument.xml","form_type":"4"}},{"id":3908580,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2018-06-05T01:28:12.000Z","date":"2018-06-01","kind":"grant","acquired":true,"shares":48720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":48720,"derivative":{"exercise_price":15.08,"expiration_date":"2028-06-01","underlying":"Common Stock","underlying_shares":48720},"source":{"system":"sec-edgar","filing":"0001562180-18-002842","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000156218018002842/primarydocument.xml","form_type":"4"}},{"id":4247444,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Series A-3 Preferred Stock","published_at":"2017-08-01T20:23:20.000Z","date":"2017-08-01","kind":"exercise","acquired":false,"shares":10557,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The expiration date is not relevant to the conversion of these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by the Lizzul Living Trust, Paul F. Lizzul and Dawn Marie Lizzul, Trustees."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10557},"source":{"system":"sec-edgar","filing":"0001140361-17-029595","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000114036117029595/doc1.xml","form_type":"4"}},{"id":4247443,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-08-01T20:23:20.000Z","date":"2017-08-01","kind":"purchase","acquired":true,"shares":10000,"price":15,"value":150000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person purchased the shares of the Issuer's common stock in connection with the Issuer's initial public offering at the offering price of $15.00 per share."}],"balance_after":94634,"source":{"system":"sec-edgar","filing":"0001140361-17-029595","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000114036117029595/doc1.xml","form_type":"4"}},{"id":4247442,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-08-01T20:23:20.000Z","date":"2017-08-01","kind":"exercise","acquired":true,"shares":10557,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are directly held by the Lizzul Living Trust, Paul F. Lizzul and Dawn Marie Lizzul, Trustees."}],"balance_after":10557,"source":{"system":"sec-edgar","filing":"0001140361-17-029595","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000114036117029595/doc1.xml","form_type":"4"}},{"id":4250223,"issuer":{"id":154554,"kind":"organization","name":"Sienna Biopharmaceuticals, Inc.","symbol":"SNNA"},"owners":[{"id":22253,"kind":"person","name":"Lizzul Paul F.","position":1,"cik":"0001711462","reported_name":"Lizzul Paul F.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-07-27T20:26:04.000Z","date":"2017-07-26","kind":"grant","acquired":true,"shares":11926,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date."}],"balance_after":11926,"derivative":{"exercise_price":15,"expiration_date":"2027-07-26","underlying":"Common Stock","underlying_shares":11926},"source":{"system":"sec-edgar","filing":"0001140361-17-028901","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1711462/000114036117028901/doc1.xml","form_type":"4"}}]}